Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortization of Deferred Charges: 2021-2024

Historic Amortization of Deferred Charges for Heron Therapeutics (HRTX) over the last 4 years, with Dec 2024 value amounting to $210,000.

  • Heron Therapeutics' Amortization of Deferred Charges fell 96.23% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $161,000, marking a year-over-year decrease of 22.60%. This contributed to the annual value of $210,000 for FY2024, which is 1.94% up from last year.
  • Per Heron Therapeutics' latest filing, its Amortization of Deferred Charges stood at $210,000 for FY2024, which was up 1.94% from $206,000 recorded in FY2023.
  • Heron Therapeutics' 5-year Amortization of Deferred Charges high stood at $210,000 for FY2024, and its period low was $119,000 during FY2021.
  • For the 3-year period, Heron Therapeutics' Amortization of Deferred Charges averaged around $206,000, with its median value being $206,000 (2023).
  • Data for Heron Therapeutics' Amortization of Deferred Charges shows a peak YoY spiked of 69.75% (in 2022) over the last 5 years.
  • Over the past 4 years, Heron Therapeutics' Amortization of Deferred Charges (Yearly) stood at $119,000 in 2021, then spiked by 69.75% to $202,000 in 2022, then grew by 1.98% to $206,000 in 2023, then increased by 1.94% to $210,000 in 2024.